Casirivimab and Imdevimab for Early Asymptomatic SARS-CoV-2 Infection, Hypothermia vs Normothermia for Cardiogenic Shock and Extracorporeal Membrane Oxygenation, Familial Idiopathic Dilated Cardiomyopathy, and more

JAMA Editor’s Summary

Casirivimab and Imdevimab for Early Asymptomatic SARS-CoV-2 Infection, Hypothermia vs Normothermia for Cardiogenic Shock and Extracorporeal Membrane Oxygenation, Familial Idiopathic Dilated Cardiomyopathy, and more

Editor’s Summary by Linda Brubaker, MD, Associate Editor of JAMA, the Journal of the American Medical Association, for the , issue.

February 1, 2022

Listen on your favorite player Take me to this show’s page

Newer →

Subcutaneous Tirzepatide for Type 2 Diabetes, Noninvasive Respiratory Strategies for COVID-19 and Acute Hypoxemic Respiratory Failure, Clinical Outcomes 1 Year After ICU Treatment for COVID-19, and more

← Older

Myocarditis After mRNA-Based COVID-19 Vaccination, Third Dose of BNT161b2 Vaccine and SARS-CoV-2 Infection Incidence, Penetrance of Deleterious Clinical Variants, and more

Facebook Twitter Buffer LinkedIn WhatsApp

Casirivimab and Imdevimab for Early Asymptomatic SARS-CoV-2 Infection, Hypothermia vs Normothermia for Cardiogenic Shock and Extracorporeal Membrane Oxygenation, Familial Idiopathic Dilated Cardiomyopathy, and more

Editor’s Summary by Linda Brubaker, MD, Associate Editor of JAMA, the Journal of the American Medical Association, for the February 1, 2022, issue.

Listen on your favorite player

New to Podcasts? It's easy to get started!

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Join Our Newsletter

We gratefully acknowledge the many organizations that have generously supported our podcasts and platform.

Network Sponsors and Advertisers

Event and Media Partners

00:00

00:00